Companion Diagnostics for Targeted Therapies Market: The U.S. Edge In Personalized Medicine

The companion diagnostics for targeted therapies market is anticipated to grow at a steady rate, which is attributable to the strong inflows of investments and strategic tie-ups in personalized medicine development that match the patient’s biological requirements. Hence, the implementation of research initiatives by global medical research agencies to overcome the challenges faced during chronic disease detection and treatment has further paved the way for future market expansion.

With the global market shifting towards new diagnostics concepts, the United States has become the epicenter of such an agility shift, supported by strategic investment focusing on new therapeutic product development to improve oncology outcomes, followed by progression in biomarker science. Hence, efforts to integrate such offerings in clinical reality are shaping the CDx market outlook in the United States.

The U.S. Transitioning Towards Molecular Matching Models

The cancer centers in the United States feature a traditional chemotherapy mindset that systematically targets cancerous cells, which has opened a new path for adopting molecular matching options. Hence, companion diagnostics (CDx) being such an option offers tailored therapies supporting precision medicine, which prolongs patients’ lives by protecting healthy cells from toxic treatments. With the prevalence of new cancer cases reaching up to 2,041,910 in 2025, according to the American Cancer Society, the transition towards effective FDA-administered treatment is gaining traction in the country.

Several other factors, like FDA willingness to support co-development models and new drug approvals supporting specific treatment plans, also provide the US a competitive edge over other major Nations like China.  Such drug approvals have accelerated timelines that showcased slow, gradual growth earlier. In the first quarter of 2025, the FDA issued 13 approvals, leveraging treatment for nine cancer types and two disorders, which showcase the US's continued progress in broadening the treatment options for patients.

Reimbursement has improved through Medicare coverage for many NGS-based tests, reflecting a growing acceptance that precision costs upfront but saves downstream. Meanwhile, the sheer volume of US clinical trials creates a virtuous cycle, focusing on more data, for better evidence and faster adoption.

Companion diagnostics have provided an optimal approach to provide targeted therapies for growing cancer cases in the United States. Commercial strategies, including drug launches, investment & collaboration, are being implemented by various biotech firms to optimize the market potential. For instance, in March 2026, Agilent Technologies Inc. received the FDA’s approval for its companion diagnostics product “PD-L1 IHC 22C3 pharmDx, Code SK006” for identifying patients with gastroesophageal junction (GEJ) carcinoma.

Role of Hybrid Testing Models in U.S. Healthcare Economics

Diagnostic criteria are witnessing a significant shift towards quick and real-time genomic profiling offers, which have provided a practical alternative for scanning and identifying various cancer types, even if tissue confirmation remains clinically important. Likewise, comprehensive laboratory service providers like Labcorp are offering genomic profiling solutions, “Labcorp Plasma Complete,” that support personalized treatment for patients with advanced solid tumors.

Hence, such evolution has further layered the companion diagnostics culture in the United States, thereby supporting the hybrid testing model adoption. Laboratories capable of integrating tissue sequencing and longitudinal disease monitoring may ultimately capture the strongest commercial positions.

Liquid biopsy technologies have become a major example of such transformation, which has initially been adopted by American healthcare systems owing to their sensitivity concerns and inconsistent reimbursement.

Ongoing Technology Convergence Is Driving Innovation

The competitive environment is becoming more intense as established diagnostics companies face pressure from emerging sequencing specialists, AI-enabled pathology firms, and integrated biotech platforms. Some incumbents still generate strong revenue through legacy PCR-based diagnostics, but long-term market momentum clearly favours multi-omic approaches capable of capturing broader biological complexity.

Moreover, artificial intelligence (AI) is also beginning to reshape interpretation workflows. Molecular profiling generates enormous datasets that many clinicians cannot easily process in routine practice. AI-assisted decision support platforms are helping bridge that gap, though physician trust still varies widely. Most oncologists do not want algorithmic medicine replacing clinical judgment, as they want systems that reduce ambiguity while preserving physician oversight.

Another interesting development is the growing role of pathology digitization as American hospital systems are gradually integrating AI with molecular and cancer diagnostics, enabling more comprehensive tumor characterization. Over time, companion diagnostics may rely less on isolated biomarkers and more on integrated biological signatures combining genomic, histological, and proteomic data.

Collaborations are taking place to bolster such development, for instance, the strategic partnership formed between Alpenglow Biosciences and PathNet in January 2026, aimed to develop and commercialize “3D-AI Enabled” diagnostics for bladder and prostate cancer.

Stringent Regulations & Investment Environment

The regulatory complexity, however, remains a real constraint, and despite FDA progress, developers still face significant hurdles around analytical validation, reimbursement coding, and clinical utility demonstration. Smaller diagnostics firms often struggle to finance late-stage validation studies independently.

Governing authorities granting funding supported by “NCI Grant Policies” have established a framework that demonstrates the US efforts to improve its oncology research. Likewise, the “FY2026 Labor, Health and Human Services, Education and Related Agencies” appropriation bills passed by the Congressional Appropriations Committee in January 2026, described funding of US$47.2 billion for the National Institutes of Health (NIH), which included US$7.35 billion for the National Cancer Institute (NCI).

Adoption Criteria: Progress with Friction

Despite ongoing investments, the market still faces margin pressures, sequencing costs continue to decline, and reimbursement competition is intensifying. Pure testing volume growth may not guarantee profitability unless companies differentiate through data analytics, proprietary biomarkers, or integrated clinical services.

Most of the hospital doesn’t have easy access to NGS infrastructure, turnaround times can still frustrate community oncologists, and interpreting complex genomic reports requires expertise that's unevenly distributed.

Precision medicine adoption depends not only on technology but also on interpretation capability. Many community oncologists remain overwhelmed by genomic complexity. Diagnostic reports can contain dozens of molecular alterations, many with uncertain clinical relevance. Educational infrastructure, therefore, becomes commercially important.

Competitive Landscape: Innovation Meets Scale

The U.S. companion diagnostics for targeted therapy market is characterized by a mix of established companies that have showcased their ability to integrate technological sophistication with practical clinical utility. Below are profiles of four notable U.S.-focused companies shaping the companion diagnostics for targeted therapy space.

Foundation Medicine (Roche)

Headquartered in Cambridge, Massachusetts, Foundation Medicine has become synonymous with comprehensive genomic profiling (CGP) in the US. The company, now part of Roche, has deep American roots and pioneers broad-panel testing that goes far beyond single-gene assays. It's “Foundation One CDx”, a tissue-based NGS test that offers genetic variation detection in 324 genes plus signatures like TMB, and holds the distinction of being the first FDA-approved broad companion diagnostic for all solid tumors. It boasts dozens of CDx indications, recently hitting a milestone of over 100 approved claims across the US and Japan.

The company has invested in strategic partnerships to support its product innovations, for instance, on 21st April 2026, Foundation Medication expanded its collaboration with Bristol Myers Squibb to develop “Foundation Once CDx” as next-generation sequencing companion diagnostics to identify patients with homozygous MTAP deletion.

Guardant Health

The company, based in Palo Alto, California, represents the liquid biopsy vanguard. Their Guardant360 CDx was the first FDA-approved comprehensive liquid biopsy for all solid tumors and has racked up multiple CDx claims across NSCLC, breast, and colorectal cancers. Recent FDA approvals include pairings for ESR1 mutations in advanced breast cancer for therapies like VEPPANU.

Guardant's approach emphasizes accessibility, for patients in rural areas or those too frail for biopsies, a simple blood draw can unlock targeted options. Palo Alto's proximity to Silicon Valley shows in its tech-forward mindset, with high-sensitivity detection of low-variant allele fractions and rapid integration into workflows. The company has largely answered doubts relating to liquid biopsy concordance with tissue via regulatory wins and payer coverage for hundreds of millions of lives. Their success underscores a broader truth: the future of CDx isn't either/or between tissue and blood, but intelligent integration of both.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific, with major operations across the US, including in California and Massachusetts, brings scalable, decentralized testing muscle. Their Oncomine Dx Target Test and newer Oncomine Dx Express Test (delivering results in as little as 24 hours on the Genexus system) are designed for implementation in local labs rather than centralized mega-facilities. This matters enormously because 85% of US cancer patients are treated outside academic centers in community hospitals.

Thermo's strategy addresses one of the market's biggest bottlenecks: turnaround time and access. By empowering community pathologists with FDA-approved NGS tools that don't require deep bioinformatics expertise, they lower the barrier to precision care.

The approval for EGFR exon 20 insertions and other markers in NSCLC demonstrates ongoing relevance. In my view, their focus on distributed diagnostics could prove more democratizing than ultra-comprehensive panels alone. US manufacturing and lab partnerships give them logistical advantages in a country this geographically vast.

Abbott Laboratories

Headquartered in Abbott Park, Illinois, brings a different but complementary strength, established molecular platforms with a track record in both FISH and PCR-based assays. While newer NGS players grab headlines, Abbott's Vysis line and real-time PCR offerings continue to serve as reliable workhorses for specific biomarkers, particularly in hematology and solid tumors. Their experience with early CDx, like ALK and HER2 tests, provides institutional knowledge that newer entrants sometimes lack.

The company’s scale in diagnostics infrastructure automation, global supply chains, and integration with core lab systems makes it a steady partner for health systems seeking reliability over bleeding-edge comprehensiveness. In an industry prone to hype cycles around new sequencing tech, this pragmatism has staying power, especially as cost pressures mount. It highlighted expanding cancer diagnostics portfolio at the “Digestive Disease Week (DDW) 2026”, in Chicago, which demonstrates its constant efforts undertaken to address critical gaps in cancer detection.

Product Innovation Snapshot (U.S.-Focused)

Such products illustrate a broader pattern of innovation and portfolio expansion concentrated in a handful of U.S. biotech hubs, particularly Illinois, California, and Massachusetts. This geographic clustering fosters collaboration but also intensifies competition.

Stakeholder’s Strategic Outlook

Investors are no longer viewing diagnostics as low-margin laboratory tools; instead, they increasingly treat them as data platforms with recurring strategic value. Molecular diagnostics companies now occupy a more central role in oncology infrastructure, particularly when they control proprietary genomic databases or AI-assisted interpretation systems.

For pharma, early CDx co-development isn't optional; it's table stakes for competitive differentiation and faster approvals. Biotech companies with sound knowledge of FDA nuances and a strong US presence gain the upper hand in attracting investment and forming collaborations with diagnostic partners. For providers, the objective is to invest in infrastructure or partner aggressively to optimize the market potential. Community systems ignoring liquid biopsy options risk losing patients to centers that offer faster, less invasive profiling.

Future Outlook: Shaping the Diagnostics Infrastructure

Though oncology is the major field of study in clinical trials in the United States, the scope expansion is navigating investments in biomarkers for various other medical areas, including neurology, immunology, and cardiology, thereby offering companion diagnostics opportunities for therapies or rare genetic conditions.

In the U.S., the market trajectory depends on several factors:

• Optimal cost of therapeutic solutions development

• Regulatory framework describing product development requirements

• Adoption of innovation concepts in data accumulation

• Integration into standard care pathways

A Market Showcasing Progressive Growth

The United States holds high market potential for the development of companion diagnostics for targeted therapies, supported by FDA approvals of new CDx modulations prepared by major firms like Thermo Fisher Scientific and Foundation Medicine Inc. With NCI grant policies in action, followed by billions of investments in oncology and advanced molecular research to bolster cancer prevention, detection, and treatment options, the market will have a suboptimal outlook.